MEDICINOVA, INC. Payments of Stock Issuance Costs
MEDICINOVA, INC. (MNOV) reported Payments of Stock Issuance Costs of $118.37 thousand for the 12-month period ending 2021-12-31, per its 10-K/A filed 2023-03-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2023-03-28
- MEDICINOVA, INC. payments of stock issuance costs for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- MEDICINOVA, INC. payments of stock issuance costs for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- MEDICINOVA, INC. payments of stock issuance costs for the quarter ending 2021-06-30 was $16.00, a 99.95% decline year-over-year.
- MEDICINOVA, INC. payments of stock issuance costs for the quarter ending 2021-03-31 was $118.35K, a 731.53% increase year-over-year.
- MEDICINOVA, INC. payments of stock issuance costs for fiscal 2021 was $118.37K, a 41.93% decline from fiscal 2020.
- MEDICINOVA, INC. payments of stock issuance costs for fiscal 2020 was $203.84K, a 29.31% decline from fiscal 2019.
- MEDICINOVA, INC. payments of stock issuance costs for fiscal 2019 was $288.37K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-28 | $0.00 derived: sum of 2 quarters · filed 2023-03-28 | $16.00 derived: sum of 3 quarters · filed 2023-03-28 | $118.37K 10-K/A · filed 2023-03-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $16.00 derived: sum of 2 quarters · filed 2022-11-10 | $118.37K 10-Q · filed 2022-11-10 | $120.84K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $16.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $118.37K 10-Q · filed 2022-08-11 | $120.84K derived: sum of 3 quarters · filed 2022-08-11 | $274.04K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $118.35K 10-Q · filed 2022-05-12 | $120.83K derived: sum of 2 quarters · filed 2022-05-12 | $274.02K derived: sum of 3 quarters · filed 2022-05-12 | $307.96K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $2.48K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $155.67K derived: sum of 2 quarters · filed 2022-02-16 | $189.61K derived: sum of 3 quarters · filed 2022-02-16 | $203.84K 10-K · filed 2022-02-16 |
| 2020-09-30 | $153.19K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $187.13K derived: sum of 2 quarters · filed 2021-11-12 | $201.36K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $33.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $48.17K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $14.23K 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $288.37K 10-K · filed 2021-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |